Maxwell Biosciences Develops a New Viral Treatment Therapeutics Platform

Maxwell Biosciences, a biotechnology company, announced patented biostable peptide analogs that function as mimics of the cathelicidin peptide - the human body’s primary virus immunity molecule. They are calling the patented small synthetic oligomers CLAROMERs™

“CLAROMER™ brand synthetic peptoid oligomers function as analogs of natural antiviral cathelicidin peptides, addressing the threat of rapidly evolving viruses by combining desirable pharmacological aspects of peptides with biostable synthetic molecules,” said Dr. Annelise Barron, Maxwell Biosciences co-founder.

Maxwell’s CLAROMER™ brand anti-infectives platformhas demonstrated powerful preclinical potency in a peer-reviewed publication that shows CLAROMER™ activity against SARS-CoV-2 and HSV-1 viruses. This paper in the Swiss journal Pharmaceuticals (MDPI) shows CryoEM images of CLAROMER™ treated viruses that reveal disruption of viral envelopes -- rendering the viral particles non-infective. CLAROMERs™ are stable in vivo and are straightforward to manufacture to purify. CLAROMERs™ also have demonstrated activity against other viruses that impact human health, including other Coronaviruses, MERS, SARS, Hepatitis B & C, Influenza A, and Rhinovirus.

The recently published pharmaceuticals article, “Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids,” was co-authored by Gill Diamond, Ph.D., who is a Maxwell Biosciences Scientific Advisory Board Member, and 10 other collaborating academic researchers.

Maxwell Biosciences CEO and co-founder, Joshua McClure, stated that with this announcement comes “a new era in peptide mimicry with biostable peptoids—an exciting new scientific approach powering the novel antivirals…”